Clinical Trials Logo

Prevalence clinical trials

View clinical trials related to Prevalence.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06201832 Recruiting - Clinical trials for Heart Failure With Preserved Ejection Fraction

Cardiac Amyloidosis in HFpEF Tunisian Patients

Amy-Card
Start date: July 1, 2023
Phase:
Study type: Observational

Cardiac amyloidosis (CA) has recently been reported as a common cause of heart failure with preserved left ventricular ejection fraction (HFpEF), with a prevalence of 6% in elderly HFpEF patients. However, the diagnosis of CA is still challenging and requires multiple costly investigations. Regardless of the type of CA, TTR or AL, early diagnosis significantly improves prognosis. In this study, the investigators aimed to determine the prevalence of CA in Tunisian HFpEF patients and to identify clinical and ultrasound criteria predictive of CA.

NCT ID: NCT06190769 Recruiting - Clinical trials for Musculoskeletal Disorders

Prevalence Of Musculoskeletal Disorders Among Monks And Nuns In Egypt

Start date: August 18, 2023
Phase:
Study type: Observational [Patient Registry]

1. Sample size will be 400. 2. Age starts from 24 years old and more. 3. Body mass index ( BMI ) between 18.5 to 24.9 kg/m2 4. Years of ordination - (1-3) years novice or probationary - (4-10) years of monasticism. - more than 10 years of monasticism. 5. Samples will be selected from several monasteries in Egypt. 6. All data collected by Arabic version of Nordic questionnaire.

NCT ID: NCT04487171 Recruiting - Covid19 Clinical Trials

Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic

COVIE-19/20
Start date: July 21, 2020
Phase: N/A
Study type: Interventional

Postpartum depression (PPD) represent around 15% of birth in developed countries. The context of the COVID-19 epidemy represents a possible source of additional emotional distress. The objective of this study is to determine the screening prevalence and risk factors of postpartum depression, among women who deliver in fourth hospital in the North of France in the context of the COVID epidemy.

NCT ID: NCT04412746 Recruiting - Diabetes Mellitus Clinical Trials

Covid-19 and Diabetes in West of Algeria

COVIDIAB-13
Start date: April 1, 2020
Phase:
Study type: Observational

By Jan 7, 2020, Chinese scientists had isolated a novel coronavirus, from patients with virus-infected pneumonia. The WHO designated later this virus as COVID-19 (coronavirus disease 2019). This exponential pandemic coronavirus infection is responsible for severe forms in 15 to 20%, for critical ill requiring ventilation in 5% and for mortality in 2%. Algeria was part of the 13 top priority countries identified by WHO based on their direct links and volume of travel to the infected provinces in China. It is known that some predisposing conditions lead to a worse outcome with coronavirus. In China, the overall case-fatality rate was 2.3%, but was higher in patients with diabetes (7.3%). In Italy, the most common comorbidities associated with death from COVID-19 were hypertension (73.8%) and diabetes (33.9%). The US Centers for Disease Control and Prevention suggests diabetes is the most common comorbidity in COVID-19 cases. In the largest cohort NHS England study, death from COVID-19 was strongly associated with uncontrolled diabetes (after full adjustment, HR 2.36). The West Algerian CORODIAB-13 study aims is (1) to assess the prevalence of diabetes among hospitalized patients with Covid-19, (2) to describe the phenotypic characteristics of patients with diabetes, and (3) to identify the parameters specific to the diabetic which are associated with severe forms. In the future, this study will provide answers for two main questions 1. Why diabetics are more at risk of developing Covid-19 infection? 2. Why diabetics are at high risk of developing severe forms?